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ABSTRACT
Introduction Peanut allergy is the the most common 
cause of life- threatening food- induced anaphylaxis. There 
is currently no effective long- term treatment. There is 
a pressing need for definitive treatments that improve 
the quality of life and prevent fatalities. Allergen oral 
immunotherapy (OIT) is a promising approach, which is 
effective at inducing desensitisation; however, OIT has 
a limited ability to induce sustained unresponsiveness 
(SU). We have previously shown that a novel treatment 
comprising a combination of the probiotic Lactobacillus 
rhamnosus CGMCC 1.3724 with peanut OIT (Probiotic 
Peanut Oral ImmunoTherapy (PPOIT)) is highly effective 
at inducing SU, with benefit persisting to 4 years after 
treatment cessation in the majority of initial treatment 
responders. Here we describe the protocol for a Phase 
IIb multicentre, double- blind, randomised, controlled trial 
(PPOIT-003) with dual primary objectives to evaluate the 
effectiveness of PPOIT at inducing SU (assessed at 8 
weeks after treatment cessation) compared with placebo 
treatment and peanut OIT alone, in children with peanut 
allergy.
Methods and analysis 200 children 1 to 10 years of age 
with current peanut allergy confirmed by failed double- 
blind placebo- controlled food challenge (DBPCFC) at study 
screening will be recruited from three tertiary paediatric 
hospitals in Australia. There are three intervention arms—
PPOIT, peanut OIT alone or placebo. Interventions are 
administered once daily for 18 months. The dual primary 
outcomes are: (1) the proportion of children who attain 
8- week SU in the PPOIT group versus placebo group and 
(2) the proportion of children who attain 8- week SU in the 
PPOIT group versus OIT group.
Ethics and dissemination This study has been approved 
by the Human Research Ethics Committees at the Royal 
Children’s Hospital (HREC 35246) and the Child and 
Adolescent Health Service (RGS 2543). Results will be 
Strengths and limitations of this study
 ► This is the first double- blind placebo- controlled 
randomised trial to examine the effectiveness of 
probiotic and peanut oral immunotherapy (Probiotic 
Peanut Oral ImmunoTherapy (PPOIT)) in inducing 
desensitisation or sustained unresponsiveness (SU) 
in children with peanut allergy compared with oral 
immunotherapy (OIT) alone.
 ► All participants will undergo a double- blindplacebo- 
controlled food challenge at study entry to confirm 
diagnosis of peanut allergy.
 ► Primary outcome of SU is assessed after 8 weeks 
of peanut elimination, longer than most published 
trials of OIT.
 ► Monitoring of patients in the post- treatment phase 
will provide new information on safety events as-
sociated with SU (with ad libitum peanut intake), 
desensitisation (with daily peanut dosing) and with 
allergen avoidance.
 ► Measurement of peanut skin prick test, peanut 
and peanut component specific IgE and specif-
ic IgG4 at study entry, end of treatment, 8 weeks 
post- treatment and 12 months post- treatment will 
provide information on immune changes associated 
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published in peer- reviewed journals and disseminated via presentations at 
international conferences.
Trial registration number ACTRN12616000322437.
INTRODUCTION
Background
The prevalence of food allergy in the paediatric popu-
lation has risen exponentially in recent decades. Now 
affecting 8%1 of children and 10% of infants,2 food 
allergy is a significant public health problem in Western 
countries.3 4 Peanut allergy affects 2% of children and 
is usually lifelong.5–7 Moreover, peanut is one of the the 
most common causes of anaphylaxis8 and death9–11 from 
food allergy.
There is currently no effective long- term treatment to 
modify the natural history of food allergy. Management 
involves avoidance of the food concerned, provision of an 
epinephrine autoinjector in some cases, and early recog-
nition of allergic symptoms and initiation of appropriate 
emergency treatment. Accidental ingestion is common, 
causing frequent and sometimes severe reactions.12 13 
Unpredictability of symptoms from unintentional inges-
tion cause significant psychological distress and reduced 
health- related quality of life for patients and their fami-
lies.14 The ultimate goal is to develop immunomodulatory 
strategies that target the underlying immune dysregula-
tion of allergic disease to induce a tolerant state, allowing 
allergic individuals to safely ingest foods on a lasting basis.
Although the precise mechanisms are incompletely 
understood, in broad terms, the development and main-
tenance of oral tolerance appears to be an active and 
antigen- specific immune response that depends on both: 
(a) exposure to allergen which induces an allergen- 
specific immune response and (b) initial allergen 
presentation in an ambient immunological milieu which 
optimally favours regulatory immune responses. It is 
therefore logical to consider both elements in thera-
peutic and preventive strategies. This is the basis of our 
treatment approach which comprises administration 
of both allergen (peanut oral immunotherapy (OIT)) 
and an adjunctive immune response modifier (IRM), 
as discussed further below. So far, most immunotherapy 
studies have focussed on food allergen delivery alone, 
without associated IRM.15 16
Tolerance can be defined as the permanent state of 
immune unresponsiveness to food antigens that does not 
require any continuing food exposure.17 Since assessing 
for permanent ‘tolerance’ is difficult within the time 
frame of clinical trials,18 the ability to induce ‘sustained 
unresponsiveness (SU)’ is used as a surrogate measure 
of more prolonged protection in food immunotherapy 
studies. SU is defined as the ability to tolerate a food 
after a period of avoidance of at least weeks or months 
and is considered to reflect redirection of the under-
lying allergic response towards tolerance. SU is opti-
mally measured by double- blind placebo- controlled food 
challenge (DBPCFC), with a cumulative dose of peanut 
protein equivalent to the amount required for diagnosis 
or exclusion of peanut allergy in the clinical setting, 
performed at least several weeks after the cessation of 
treatment.19 Another outcome that can be achieved with 
food immunotherapy is desensitisation, defined as a tran-
sient increase in reaction threshold that is only main-
tained with continuing and regular allergen exposure. 
Desensitisation reflects downregulation of effector cell/
mast cell activation without redirection of the underlying 
allergic response.
OIT has garnered intense interest as a potential food 
allergy treatment. OIT has been shown to consistently 
induce desensitisation in a high proportion of partici-
pants; however, effectiveness of OIT to induce SU appears 
to be modest.15 20 Few studies have examined for SU 
following peanut OIT. The first uncontrolled open- label 
study of peanut OIT (maintenance dose 125 mg peanut 
protein for 22 months) reported SU in 13% (3/23) of 
treated children.21 A second uncontrolled study (4 g 
peanut protein for 5 years) reported SU in 31% (12/39) 
of OIT- treated patients by intention- to- treat analysis (ITT) 
(or 50% (12/24) by per protocol analysis).18 As there was 
no control group in either of these studies, it is difficult 
to ascertain the benefit from OIT over and above natural 
resolution which can occur in ~20% of children within 
5 years.5 22 A third open- label controlled study of peanut 
OIT (4 g peanut protein for 2 years) in 43 patients 5 to 
45 years of age reported SU in 30.4% (7/23) of the OIT 
group compared with 0% (0/20) of control patients.23 
The only double- blind, randomised, placebo- controlled 
trial of peanut OIT24 that evaluated SU as an outcome 
randomised 120 peanut allergic patients (aged 7 to 55 
years) to receive: (1) peanut OIT (maintenance 4 g) for 
104 weeks followed by peanut discontinuation (peanut-0, 
n=60), (2) peanut OIT (maintenance 4 g) for 104 weeks 
followed by 300 mg peanut daily (peanut-300, n=35) or 
(3) oat flour for 104 weeks followed by peanut avoidance 
(placebo group, n=25). All participants were followed for 
3 years (156 weeks). DBPCFC was performed at week 104, 
117, 130, 143 and 156. The rate of SU (defined as those 
passing both the week 104 and 117 challenges) in the 
peanut-0 group was 35% (21/60), compared with 4% in 
the placebo group.24 These studies show that while OIT 
can induce SU in some patients, effectiveness appears to 
be limited.
Patients with ‘desensitisation’ (without evidence of SU) 
remain at risk of allergic reactions to allergen, including 
to previously tolerated doses, despite continuing with 
regular allergen exposure. Studies indicate that chil-
dren who have been desensitised following OIT experi-
ence allergic reactions, including anaphylaxis requiring 
epinephrine treatment, more frequently than if they had 
continued with traditional food avoidance management 
strategies.25–28 This highlights the importance of identi-
fying an effective immunomodulatory therapy that can 
induce SU or tolerance, which are expected to provide 
greater benefit and safety to individuals with food allergy 
than is achieved by desensitisation.
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We postulated that IRM may enhance the ability of 
allergen OIT in inducing SU and tolerance. IRM are a 
class of tolerogenic compounds, typically of microbial 
origin, which modulate immune responses by acting 
on antigen- presenting cells through pattern recogni-
tion receptors, including Toll- like receptors. One well- 
characterised IRM is the probiotic bacteria Lactobacillus 
rhamnosus GG, with demonstrated immunomodulatory 
effects in vitro and in vivo that can support acquisition of 
oral tolerance, including induction of T regulatory and 
Th1 cytokine responses.29–32 Furthermore, oral co- admin-
istration of L. rhamnosus GG with antigen has been shown 
to enhance antigen- specific IgA responses, which are also 
known to promote oral tolerance.33 34
In a landmark forerunner study to the current trial, we 
reported the first randomised controlled trial (RCT)35 
evaluating a combination of probiotic L. rhamnosus 
CGMCC 1.3724 (which is genetically indistinguishable 
from L. rhamnosus GG) together with probiotic and 
peanut OIT (Probiotic Peanut Oral ImmunoTherapy 
(PPOIT)).35 Sixty- two children with peanut allergy were 
randomised to receive either PPOIT or placebo for 18 
months. The probiotic L. rhamnosus CGMCC 1.3724 was 
administered as a fixed daily dose (2×1010 cfu), while the 
peanut OIT was a daily dose of peanut protein starting 
at low doses and increasing to a maintenance dose of 2 g 
peanut protein. SU was assessed by DBPCFC performed 
4 (±2) weeks after cessation of treatment. Eighty- two 
per cent of PPOIT- treated participants achieved SU to 
peanut compared with only 3.6% of placebo- treated chil-
dren. PPOIT treatment was also associated with reduced 
peanut SPT and specific IgE (sIgE), and increased peanut 
specific IgG4 (sIgG4), suggesting modulation of the 
underlying allergic response to peanut. Furthermore, the 
clinical benefit of PPOIT was shown to be long- lasting, 
with 70% of PPOIT- treated children who achieved SU at 
the end of treatment still having challenge- confirmed SU 
at 4 years after end of treatment (assessed by DBPCFC 
performed following 8 weeks of peanut elimination).36 
For logistic reasons, this preliminary study did not 
compare PPOIT with OIT alone. Having demonstrated 
that PPOIT is highly effective at inducing long- lasting SU 
in children with peanut allergy, it is now imperative to 
examine whether the combined PPOIT treatment is more 
effective than peanut OIT at inducing SU, and hence to 
determine if the probiotic IRM does indeed offer added 
benefit over and above peanut OIT alone. It is also neces-
sary to confirm the previous findings in a larger multi-
centre randomised trial.
This paper reports the research protocol for a Phase 
IIb multicentre, double- blind placebo- controlled 
randomised trial evaluating the efficacy of PPOIT at 




1. To compare the proportion of children who attain 8- 
week SU in PPOIT and placebo- treated groups.
2. To compare the proportion of children who attain 8- 
week SU in PPOIT and OIT- treated groups.
Secondary objectives
1. To compare the proportion of children who attain 8- 
week SU (passed T1 and T2 challenges) in OIT and 
placebo- treated groups.
2. To compare the proportion of children who achieve 
full desensitisation (passed T1 challenge) at the end 
of treatment in (1) PPOIT versus placebo; (2) PPOIT 
versus OIT; and (3) OIT versus placebo.
3. To compare the total cumulative dose of peanut pro-
tein tolerated during the end- of- treatment T1 chal-
lenge in (1) PPOIT versus placebo; (2) PPOIT versus 
OIT; and (3) OIT versus placebo. This will determine 
the total dose tolerated in partially desensitised (those 
who did not achieve full desensitisation) and allergic 
participants.
4. To compare the proportion of children who are eating 
peanut in their diet 12 months after end of treatment 
in (1) PPOIT versus placebo; (2) PPOIT versus OIT; 
and (3) OIT versus placebo.
5. To compare peanut skin prick test (SPT) and peanut 
and peanut component sIgE and sIgG4 levels at the 
end of treatment, and at 8 weeks and 12 months after 
treatment in PPOIT, OIT and placebo groups; and to 
examine their correlation with SU.
6. To evaluate the safety and tolerability of PPOIT.
Exploratory objectives
1. To compare quality of life at the end of treatment and 
12 months later in PPOIT, OIT and placebo groups.
2. To determine cost- effectiveness of PPOIT compared 
with OIT and placebo in terms of achieving SU, full 




This is a three- armed, multicentre, randomised (2:2:1), 
stratified (by study site, age and SPT), blinded, placebo- 
controlled, parallel- group superiority trial
 ► PPOIT=Probiotic and peanut OIT taken daily for 18 
months.
 ► OIT=Probiotic placebo and peanut OIT taken daily 
for 18 months.
 ► Placebo=Probiotic placebo and OIT placebo taken 
daily for 18 months.
Study setting
This is a multicentre study conducted in three children’s 
hospitals in Australia—the Royal Children’s Hospital 
(RCH) in Melbourne, Perth Children’s Hospital (PCH) 
in Nedlands, and the Women’s and Children’s Hospital 
(WCH) in Adelaide. Participants recruited from allergy 
departments of these tertiary hospitals and from the 
general community reached by the media.
P
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Initiation and updosing of immunotherapy will be 
performed in hospital/clinical research facility by nursing 
and medical staff experienced in the performance of 
food challenges, OIT and management of allergic reac-
tions. Interim doses of OIT will be administered at home.
All participants will be provided with an anaphylaxis 
action plan and an EpiPen/Epipen Jr, and educated in 
the management of allergic reactions (standard care 
for peanut allergy). If a reaction occurs, they will follow 
the anaphylaxis action plan, and notify the on- call study 
personnel at the local study site.
Participants and eligibility criteria
Two hundred children, 1 to 10 years of age, with current 
peanut allergy confirmed by DBPCFC at study screening. 
Participants will be randomised to PPOIT (n=80), OIT 
(n=80) or placebo (n=40).
Participant eligibility was established prior to enrol-
ment and randomisation.
Inclusion criteria
Participants were eligible for the study if they met all 
the following criteria:
 ► Children aged between 1 and 10 years.
 ► >7 kg (the weight considered safe for the administra-
tion of an EpiPen Jr).
Confirmed diagnosis of peanut allergy as defined by a 
failed DBPCFC with peanut and a positive SPT or sIgE to 
peanut at screening visit (a positive SPT is defined as weal 
size ≥3 mm and a positive sIgE is defined as >0.35 kUA/L).
Exclusion criteria
Participants were not eligible for the study if they met 
any of the following criteria:
 ► History of severe anaphylaxis (as defined by persis-
tent hypotension, collapse, loss of consciousness, 
persistent hypoxia or ever needing more than three 
doses of intramuscular epinephrine or an intravenous 
epinephrine infusion for management of an allergic 
reaction).
 ► Severe anaphylaxis during the study entry DBPCFC.
 ► Forced expiratory volume in 1 second (FEV1) <85% 
predicted at rest and FEV1/FVC (forced vital capacity) 
≤85% at rest or ongoing chronic persistent asthma (as 
per National Asthma Council guidelines).
 ► Underlying medical conditions (eg, cardiac disease) 
that increase the risks associated with anaphylaxis.
 ► Use of beta- blockers and ACE inhibitors.
 ► Inflammatory intestinal conditions, indwelling cath-
eters, gastrostomies, immune- compromised states, 
post- cardiac and/or gastrointestinal tract surgery, 
critically ill and those requiring prolonged hospitali-
sation or other conditions that may increase the risks 
of probiotic- associated sepsis.
 ► Already taking probiotic supplements within the past 
6 months (does not include formula).
 ► Reacting to the placebo component during the study 
entry DBPCFC.
 ► Have received other food immunotherapy treatment 
in the preceding 12 months.
 ► Currently taking immunomodulatory therapy 
(including allergen immunotherapy).
 ► Past or current major illness that in the opinion of 
the site investigator may affect the patient’s ability to 
participate in the study; for example, increased risk to 
the participant.
 ► Patients who, in the opinion of the site investigator, 
are unable to follow the protocol.
 ► Another family member already enrolled in the trial 
(to maintain safety and blinding).
Patient recruitment, study procedure and data collection
The start date of the trial was 4 July 2016 and the planned 
end date is October 2020.
Consent procedure
Participants who are identified as potentially being suit-
able to participate in the study and their parents will be 
sent an Information Statement and Consent Form as 
approved by the RCH and local site Human Research 
Ethics Committee (HREC) and Research Governance 
Office.
Prior to full study enrolment and gathering any further 
study- specific personal information or performing any 
study- specific procedures (eg, screening DBPCFC), a 
signed consent form will be obtained from the parent(s) 
or guardian of the participant. Randomisation and 
enrolment will take place up to 1 week prior to the Rush 
Induction visit (initiation of study treatment). The Rush 
Induction visit may be delayed up to 3 months after 
screening visit.
Randomisation and concealment mechanism
Participants will be enrolled and randomised up to 1 week 
prior to Rush Induction, and within 3 months of their 
screening appointment. Randomisation will be to PPOIT, 
OIT or placebo groups, with an allocation ratio of 2:2:1. 
Randomisation will be stratified by study site (RCH, PCH 
and WCH), by age (1 to 5 years; 6 to 10 years) and by peanut 
SPT weal size (≤10 mm; >10 mm). Stratification by age and 
SPT weal size is necessary for data analysis because younger 
age and smaller SPT size are associated with a greater like-
lihood of natural resolution. Each study site will have their 
own randomisation list stratified by age and peanut SPT weal 
size. Randomisation will be in randomly permuted blocks of 
variable length. An independent statistician in the Clinical 
Epidemiology and Biostatistics Unit (CEBU) at the Murdoch 
Children’s Research Institute (MCRI) will provide the rando-
misation schedules to hospital pharmacies at each site.
Participant eligibility will be established prior to enrol-
ment and randomisation. A unique participant screening 
number will be allocated to each consenting participant 
prior to proceeding with study screening. Participants who 
are confirmed as eligible for the study after the screening visit 
(including having failed the screening DBPCFC) will have an 
appointment made for Rush Induction and study personnel 
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Participants will be enrolled into the trial in strict sequence 
as their eligibility for enrolment is determined. Randomisa-
tion and enrolment will only be performed up to 1 week prior 
to Rush Induction—a small number of participants who are 
eligible for the study at study screening may decide not to 
proceed with the study between the challenge and the Rush 
Induction day.
The pharmacist will assign the next available unique rando-
misation number for the participant’s appropriate stratum 
using the randomisation list and notify the trial personnel of 
that number. This randomisation number will be recorded 
on the participant’s CRF (case report form). The pharma-
cist will prepare the participant’s allocated study treatment 
and label the treatment with the participant’s randomisation 
number. Participants, outcome assessors, other research staff, 
treating clinicians, investigators and statistical analyst will be 
blinded to treatment allocation.
Probiotic (or placebo) and peanut (or placebo) OIT regimen
Rush induction visit (T0)—day 1
In this phase, participants will receive a single dose 
of 2×1010 cfu L. rhamnosus GG or placebo followed by 
increasing doses of peanut (or placebo) OIT, to reach a 
final dose of 12 mg of peanut protein or placebo (cumu-
lative dose 24 mg peanut protein or placebo).
Participants who complete the Rush protocol without 
reaction will commence the Buildup Phase at a daily dose 
of 25 mg peanut protein or placebo on the day after the 
Rush Induction day. However, if a participant reacts to one 
of the doses during Rush Induction, the rush schedule 
will be ceased and they will commence the Buildup Phase 
at the dose immediately below the reaction- eliciting dose 
starting on the day after the Rush Induction day.
Buildup phase
In the Buildup Phase, the daily dose of peanut OIT 
(or placebo OIT) will be increased every 2 weeks until 
a maintenance dose of 2000 mg is reached. Each dose 
increase will be administered in hospital under medical 
supervision.
Participants will also take a fixed dose of 2×1010 cfu L. 
rhamnosus GG or placebo once daily prior to the OIT 
treatment.
Parents will maintain a daily diary record of dosing, 
compliance, reactions to study product and any treat-
ments administered for reactions during the whole time 
of the study.
Maintenance phase
In this phase, participants will take a daily dose of 2 g 
peanut protein or placebo and a daily dose of 2×1010 cfu 




Sustained unresponsiveness—time point T2
SU will be assessed by DBPCFC performed at 8 weeks 
after cessation of study treatment. The procedure of 
DBPCFC will be the same as described in the screening 
visit. Only those participants who pass the desensitisation 
DBPCFC at the T1 visit will proceed to the SU DBPCFC 




Desensitisation will be assessed by DBPCFC performed 
1 day after the last day of treatment (at time point T1). 
Participants who pass the T1 DBPCFC will be considered 
to have achieved desensitisation.
Peanut intake and reactions—time point T3
Peanut intake and reactions to peanut will be recorded in 
the participant’s diary during the period between T1 and 
T3. Participant/parents will be given a ‘Follow- up Diary’ 
at T1 (if participant fails T1 DBPCFC) or at T2 (if partic-
ipant passes T1 DBPCFC) to record reactions to peanut 
or other food products, and also peanut consumption. 
Participants are provided with instructions for peanut 
ingestion/avoidance based on their treatment outcomes: 
(1) participants who achieve SU at the end of treatment 
will be instructed to incorporate peanut into their diet 
ad libitum, (2) participants who achieve desensitisation 
without SU will be instructed to commence a daily inges-
tion of 1 to 2 peanuts while maintaining avoidance of all 
other peanut intake, and (3) participants who remain 
allergic to peanut will be advised to continue strict avoid-
ance of peanut in their diet. Participants/parents will 
maintain the diary from T1/T2 to T3 and data will be 
collected from the participant’s diary at the T3 visit.
Study outcomes
Primary outcomes
 ► Proportion of participants with 8- week SU (passed T1 
and T2 challenges) in PPOIT versus placebo.
 ► Proportion of participants with 8- week SU (passed T1 
and T2 challenges) in PPOIT versus peanut OIT.
Secondary outcomes
 ► Proportion of participants with 8- week SU (passed T1 
and T2 challenges) in peanut OIT versus placebo.
 ► Proportion of participants who achieve full desensiti-
sation (passed T1 DBPCFC) in PPOIT versus placebo, 
PPOIT versus OIT, and OIT versus placebo.
 ► The cumulative dose tolerated during the T1 chal-
lenge—determined by performing a DBPCFC—
(cumulative doses below the reaction- eliciting dose if 
there is a reaction; or total cumulative challenge dose 
if there is no reaction) in: (1) PPOIT versus placebo; 
(2) PPOIT versus OIT; and (3) OIT versus placebo.
 ► Proportion of participants who are eating peanut in 
their diet without reaction at 12 months after the 
cessation of treatment in: (1) PPOIT versus placebo; 
(2) PPOIT versus OIT; and (3) OIT versus placebo.
 ► Change in peanut SPT weal size at end of treatment, 
and 8 weeks and 12 months after the end of treatment 
P
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in: (1) PPOIT versus placebo; (2) PPOIT versus OIT; 
and (3) OIT versus placebo.
 ► Change in immunological measures (sIgE and sIgG4) 
at the end of treatment, and 8 weeks and 12 months 
after the end of treatment in: (1) PPOIT versus 
placebo; (2) PPOIT versus OIT; and (3) OIT versus 
placebo.
 ► Correlation between change in peanut SPT weal size 
and SU at the end of treatment, and 8 weeks and 12 
months after the end of treatment in: (1) PPOIT 
versus placebo; (2) PPOIT versus OIT; and (3) OIT 
versus placebo.
 ► Correlation between change in immunological meas-
ures (sIgE and sIgG4) and SU at the end of treatment, 
and 8 weeks and 12 months after the end of treatment 
in: (1) PPOIT versus placebo; (2) PPOIT versus OIT; 
and (3) OIT versus placebo.
 ► Incidence and severity of treatment- emergent adverse 
events in PPOIT, OIT and placebo groups.
 ► Peanut intake (accidental or intentional) from the 
end of treatment to 12 months post- treatment.
 ► Reactions to peanut from the end of treatment to 12 
months post- treatment.
Exploratory outcomes
 ► Quality of life score at the end of treatment and at 
12 months after the end of treatment in: (1) PPOIT 
versus placebo; (2) PPOIT versus OIT; and (3) OIT 
versus placebo.
 ► Cost per case of SU, full desensitisation and quality- 
adjusted life year gained at 12 months post- treatment.
Study outline described in figure 1.
Study visits
T0 visit
The following assessments will be conducted at the day 1 
Rush Induction visit (T0):
 ► Allergy questionnaire.
 ► Vital signs (blood pressure*, pulse, respiration and 
temperature).
 ► Spirometry (all children over 8 years).
 ► Weight/height.
 ► Faecal sample (collected by parents at home).
 ► Anaphylaxis education.
 ► Dispense participant diary.
 ► Anaphylaxis action plan and EpiPen prescribed.
 ► Dispense OIT.
Buildup phase visits
The following assessments will be conducted at these 
visits:
 ► Allergy questionnaire.
 ► Vital signs (blood pressure*, pulse, respiration and 
temperature).
 ► Weight/height.
 ► Anaphylaxis education.
 ► Review participant diary.
 ► Collect study treatments for review of compliance.
 ► Dispense OIT.
 ► Review adverse events and concomitant medications.
Maintenance phase visits
The following assessments will be conducted at these 
visits:
 ► Allergy questionnaire.
 ► Vital signs (blood pressure*, pulse, respiration and 
temperature).
 ► Weight/height.
 ► Anaphylaxis education.
 ► Review participant diary.
 ► Provide faecal collection pot and instructions (for 
collection at T1).
 ► Collect study treatments for review of compliance.
 ► Dispense OIT.
 ► Review adverse events and concomitant medications.
T1 visit
There will be a study visit at 18 months (T1, end of treat-
ment) for assessment of desensitisation.
The following assessments will be conducted at this visit:
 ► Medical history.
 ► Allergy questionnaire.
 ► Vital signs (blood pressure*, pulse, respiration and 
temperature).
 ► Spirometry (all children over 8 years).
 ► Weight/height.
 ► Parent(s) to complete Food Allergy Quality of Life- 
Parent Form (FAQL- PF).
 ► SPT (peanut, egg, milk, cashew, almond, pista-
chio, hazelnut, dust mite, and positive and negative 
control).
 ► Anaphylaxis education.
 ► Review participant diary.
 ► Collect study diary and dispense new diary once 
allergic status known.
 ► Collect study treatments for review of compliance.
 ► Review adverse events and concomitant medications.
 ► DBPCFC.
 ► Blood and faecal sample (faecal sample collected by 
parents at home).
 ► Provide faecal collection pot and instructions (for 
collection at T2).
Figure 1 Study outline. DBPCFC, double- blind placebo- 
controlled food challenge; mths, months; OIT, oral 
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T2 visit
There will be a visit at 20 months (T2, 8 weeks after T1) 
for assessment of SU.
The following assessments will be conducted at this visit:
 ► Medical history.
 ► Allergy questionnaire.
 ► Vital signs (blood pressure*, pulse, respiration and 
temperature).
 ► Spirometry (all children over 8 years) (only if they 
pass T1 DBPCFC).
 ► Weight/height.
 ► SPT (peanut, egg, milk, cashew, almond, pista-
chio, hazelnut, dust mite, and positive and negative 
control).
 ► Anaphylaxis education.
 ► Review participant diary.
 ► Collect study diary and dispense new diary once 
allergic status known.
 ► Review adverse events and concomitant medications.
 ► DBPCFC (only if they pass T1 DBPCFC).
 ► Blood and faecal sample (faecal sample collected by 
parents at home).
*For participants ≤3 years of age, blood pressure read-
ings will be at the medical staff’s discretion.
6 months post-treatment phone call
The following assessments will be conducted:
 ► Allergy questionnaire.
T3 visit
The T3 visit will be performed 12 months after the end 
of treatment (T1). During this visit, peanut ingestion and 
reactions to peanut in the 12- month period since the end 
of treatment will be recorded.
Study procedures
Double-blind placebo-controlled food challenge
Each DBPCFC will comprise two parts performed on two 
separate days, which are completed within 1 week of each 
other and at least 24 hours apart. The cumulative amount 
of peanut or placebo powder administered is 9.9 g (equiv-
alent to 4950 mg of peanut protein) (table 1). The doses 
will be administered at 15 min intervals, if the participant 
has not had a reaction consistent with a predefined stop-
ping criteria (box 1) to the previous dose. The partici-
pant will be observed for a minimum of 2 hours following 
food challenge and will be discharged home if no adverse 
reactions are noted.
Food challenge protocol and stopping criteria are 
shown in table 1 and box 1.
The DBPCFC will be classified as:
 ► ‘Failed’ if there is a reaction to the peanut compo-
nent and no reaction to the placebo component 
(pharmacy will only un- blind the contents of part A 
and B after both parts are completed and provided 
the participant has failed one part and not the other 
part of the DBPCFC).
 ► ‘Passed’ if both part A and B of the challenge are 
completed without reaction. The contents of part A 
and B are not be un- blinded.
 ► ‘Inconclusive’ if participant reacts to both part A and 
B (contents of part A and B will not be un- blinded) 
or if participant reacts to the placebo component but 
not the active component.
Severity grading for allergic reactions is based on the 
National Institutes of Health- National Institute of Allergy 
and Infectious Diseases (NIH NIAID) Consortium for 
Food Allergy Research- specific grading system for allergic 
reactions.37
Skin prick test and laboratory tests
At the time of the screening visit as well as the end of treat-
ment (T1), and at 8 weeks (T2) and 12 months (T3) after 
end of treatment, up to 20 mL of blood will be collected 
for the measurement of sIgE and sIgG4 against whole 
peanut and peanut components (Ara h 1, Ara h 2 and 
Ara h 3) by ImmunoCAP (Phadia AB, Uppsala, Sweden). 
Plasma and peripheral blood mononuclear cells will be 
isolated and stored at −80°C or in liquid nitrogen for 
exploratory immunological studies.
SPT for peanut, egg, milk, cashew, almond, pistachio, 
hazelnut, dust mite, and positive and negative control will 
be performed at the same times as blood collection.
Stool samples will also be collected at various times and 
stored at −80°C for future microbial studies.











1 80 160 80 
2 160 320 240 
3 320 640 560 
4 640 1280 1200 
5 1250 2500 2450 
6 2500 5000 4950 
ViCTOR, Victorian Children’s Tool for Observation and 
Response.
Box 1 Cessation criteria for DBPCFC
Any of the following objective signs occurring within 2 
hours of ingestion:
 ► Three or more concurrent non- contact urticaria persisting for at 
least 5 min.
 ► Perioral, periorbital or facial angio- oedema.
 ► Vomiting (excluding gag reflex) and/or diarrhoea.
 ► Persistent cough (ie, not just intermittent and transient throat clear-
ing), wheeze (either audible (without stethoscope) or on auscultation 
with stethoscope), change in voice, stridor, difficulty breathing and 
long bursts of sneezing/persistent rhinorrhoea (persistent defined as 
on three or more doses or more than 40 min).
 ► Collapse, hypotension (ViCTOR chart).
P
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Participant compliance
Participants will be asked to bring their study medica-
tion to each study visit. Compliance will be monitored by 
parent diary records as well as by treatment capsule/tub 
counts and weighing of returned bottle contents.
Adverse events reporting
Adverse events will be recorded from signed consent 
until 8 weeks after the last dose of study product in the 
participants’ diary. Participants will be able to record any 
concern or adverse event in the diary for review at each 
study visit. Causality will be assessed by study doctors, 
using the following categories: unrelated, unlikely to 
be related, possibly related and probably related. The 
severity of an adverse event will be assessed and cate-
gorised according to whether the event is an allergic 
reaction or a non- allergic reaction. If the adverse event 
is an allergic reaction, the severity of the event will be 
categorised based on criteria adapted from the NIAID 
Consortium for Food Allergy Research- specific grading 
system for allergic reactions. For all other adverse 
events (ie, events which are not allergic reactions), the 
severity of the event will be classified according to the 
International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use 
(ICH) guidelines.
Statistical methods
Sample size and power calculation
The study sample size will be 200 participants, randomly 
allocated in a 2:2:1 ratio to PPOIT (n=80), OIT (n=80) 
and placebo (n=40). Since the study aims to assess two 
primary treatment comparisons, a hierarchical ‘fixed- 
sequence’ testing strategy will be used to maintain a 
global type I error of 5% for the study.
For the first treatment comparison, PPOIT versus 
placebo, we conservatively estimate a proportion of 60% 
of participants will achieve SU with PPOIT based on 
the results of our previous RCT;35 and the natural rate 
of resolution of peanut allergy is conservatively assumed 
to be equal to or below 15%.35 Applying a 2:1 ratio for 
randomisation to PPOIT and placebo arms, sample sizes 
of n=70 and n=35 will provide >99% power with two- tailed 
0.05 significance level for the Pearson χ2 test to detect the 
difference between 60% SU in the PPOIT group and 15% 
in the placebo group.
For the second treatment comparison, PPOIT versus 
OIT, a pilot study of peanut OIT reported SU in 30% of 
participants.23 A sample size of n=70 in PPOIT and n=70 
in OIT groups will provide 85% power with two- tailed 
0.05 significance level to detect the difference between 
60% SU in the PPOIT group and 35% in the OIT group.
Allowing for a 12.5% loss to follow- up, we will recruit 
200 children, resulting in approximately 80 children in 
each of the PPOIT and OIT groups, and 40 in the placebo 
group. In our completed RCT, loss to follow- up was 10%.
Statistical analysis
Data handling, verification and analysis will be performed by 
an independent clinical research organisation, Datapharm 
Australia, in collaboration with the CEBU at MCRI. Statistical 
analysis will follow standard methods for randomised trials 
and the primary analysis will be by ITT.
All available data from all participants who received any 
investigational product will be included in the analysis of the 
safety data.
All demographic and baseline continuous outcomes will 
be presented as mean and standard deviation (or medians 
and IQRs for skewed data), while categorical outcomes will 
be presented as absolute and relative frequencies in the three 
groups.
Unless specified otherwise, statistical tests will be 
conducted at the 5% significance level (alpha) and all CIs 
will be reported as 95%.
The primary analysis will be conducted when all partici-
pants have either completed the T2 visit or terminated the 
study prior to their T2 DBPCFC. At the completion of the 
last T2 visit, database lock and statistical analyses on the 
primary and secondary outcomes to the T2 time point will be 
conducted by an independent unblinded statistician (Data-
pharm Australia). Participants and study staff will remain 
blinded to treatment allocation and will continue onto the 
Monitoring (non- treatment) phase. When all participants 
have either completed the T3 visit or terminated the study 
prior to T3, the final database lock will occur and statistical 
analyses on the secondary outcomes to T3 time point and 
exploratory outcomes will be performed.
Primary outcomes
The primary endpoint is whether a participant has SU 
(passed T1 and T2 challenges). Results will be summarised 
as the number and proportion of participants with SU in the 
three treatment groups. Comparison between PPOIT with 
placebo as well as between PPOIT with OIT will be presented 
as risk differences and relative risks, accompanied by their 
95% CI, with the null hypothesis of no difference between 
the groups tested using Pearson χ2 statistic. Moreover, logistic 
regression analysis with adjustment for the stratification 
variables (centre, age category and SPT weal size category) 
used in the randomisation, will be conducted and ORs with 
respective CIs reported.
Secondary outcomes
Group comparisons (PPOIT versus placebo; PPOIT versus 
OIT; and OIT versus placebo) regarding dichotomous 
outcomes will be presented as risk differences and relative 
risks, accompanied by their 95% CI, as well as using OR esti-
mates with 95% CIs, obtained from a logistic regression anal-
ysis with adjustment for the stratification variables used in the 
randomisation.
If normally distributed, continuous outcomes will be 
compared using differences between mean values, estimated 
from linear regression models. In particular, peanut SPT 
weal size, sIgE and sIgG4 levels will be reported as mean 
and SD by treatment group, and presented at the end of 
P
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treatment (T1), at T2 and at the end of study (T3). The 
difference in mean between groups and the corresponding 
95% CIs (PPOIT versus placebo; PPOIT versus OIT; and OIT 
versus placebo) will be obtained by using an unadjusted and 
adjusted (by stratification variables used in the randomisa-
tion) linear regression and the hypothesis of no difference 
between the groups tested with a t- test. Analogously, quality 
of life continuous outcome measures will be summarised 
by treatment group at the end of treatment (T1) and the 
end of study (T3) and presented as a difference in means 
between groups and the corresponding 95% CI (PPOIT 
versus placebo and PPOIT versus OIT), obtained by using 
unadjusted and adjusted linear regression. If continuous 
outcomes do not follow normal distributions, they will 
be summarised as median and IQR in the three groups, 
and comparison between groups will be performed by the 
Wilcoxon rank- sum (Mann- Whitney) test. The cumulative 
tolerated dose at the T1, which is inherently non- normally 
distributed, will be will be presented as medians and IQR by 
treatment groups and compared between treatment groups 
in pairwise fashion using the Wilcoxon rank- sum test.
A per- protocol analysis will also be performed whereby 
participants will be excluded if they completed less than 68 
weeks of study treatment, or are recorded to have intake of 
probiotic supplements or products containing the probiotic 
L. rhamnosus GG on 30 or more days of the active treatment 
period, or are recorded to have intake of peanut on 30 or 
more days of the active treatment period or do not have the 
primary outcome data available or treatment compliance is 
not between 80% and 120% for both the buildup and main-
tenance phases of the study.
Safety tables will present the frequency and percentage of 
participants with an adverse event and the number of events, 
by relationship to study drug (unrelated, unlikely to be 
related, possibly related and probably related), by severity, by 
study phase and according to whether the event is an allergic 
reaction or a non- allergic reaction. Similar separate summa-
ries of serious adverse events (SAEs) will also be provided.
Full details of the primary and secondary statistical analyses 
will be specified in a separate statistical analysis plan (SAP) 
which will be finalised before study database lock. The SAP 
will detail covariates to be considered in the primary anal-
ysis model as well as subgroup and sensitivity analyses to be 
performed. The SAP will also outline the imputation strategy 
to handle missing data.
Study oversight (data and safety monitoring)
The Sponsor is responsible for monitoring the progress 
of the trial, protocol compliance and ensuring the study is 
being conducted according to ethical and relevant regulatory 
requirements.
In this trial an independent data and safety monitoring 
committee (DSMC) has been appointed to review all serious 
adverse and non- serious events in the whole study popu-
lation. The DSMC will meet annually or more frequently 
if needed. The DSMC consists of a biostatistician and two 
paediatric allergist immunologists. SAEs will be reported to 
the RCH and site- specific HREC.
All data reported to the DSMC will be presented 
according to blinded treatment groups, with treatment 
groups labelled as ‘A’, ‘B’ and ‘C’. However, if necessary, 
unblinded data can be obtained by an independent statis-
tician and only be made available to the DSMC.
During the study, the Sponsor or its representatives 
(including an independent Clinical Research Organisation) 
will make site visits to review protocol compliance and ensure 
the study is being conducted according to ethical and rele-
vant regulatory requirements.
Patient and public involvement
Patients and the public were not involved in the develop-
ment of this study protocol.
ETHICS AND DISSEMINATION
This study will be conducted with the principles of Good 
Clinical Practice. The RCH HREC (HREC 35246) and Child 
and Adolescent Health Service HREC have approved this 
trial. Written informed consent will be obtained for all trial 
participants from their parent(s) or guardians. Consent will 
be voluntary and free from coercion, and participants are 
free to withdraw at any time without this affecting their future 
care. The confidentiality of participants will be protected at all 
times. Results will be published in peer- reviewed journals and 
disseminated via presentations at international conferences.
This paper is based on the PPOIT-003 V.11, 30 May 
2019.
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